{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10"}],"title":"MRD positive"},{"measurements":[{"groupId":"OG000","value":"17"}],"title":"MRD negative"},{"measurements":[{"groupId":"OG000","value":"1"}],"title":"Not Evaluable"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"}],"units":"Participants"}],"description":"Minimal Residual Disease (MRD) was assessed for all participants as soon as they achieved CR/sCR, regardless of what phase they were on.\n\nMRD negativity is defined as the complete absence of plasma cells on bone marrow biopsy.\n\nMRD positivity is defined as the presence of residual plasma cells (\\<5%) on bone marrow biopsy.\n\nThe IMWG criteria were used to determine CR and sCR.","groups":[{"description":"Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) \\[Car-BiRD\\]\n\nCar Phase:\n\ncarfilzomib: 45 mg/m2 IV on days 1, 2, 8, 9, 15 and 16 of each 28 day cycles. Dexamethasone: 20 mg orally on days 1, 2, 8, 9, 15 and 16 of a 28 day cycle, while receiving carfilzomib.\n\nBiRD Phase:\n\nClarithromycin: 500 mg twice a day for each 28 day cycle of BiRD treatment. BiRD begins after carfilzomib treatment has been completed.\n\nLenalidomide: 25 mg orally days 1-21 for each 28 day cycle of BiRD treatment. BiRD begins after carfilzomib treatment has been completed.\n\nDexamethasone: 40 mg orally on days 1, 8, 15 and 22 of each 28 day cycle of BiRD treatment. BiRD begins after carfilzomib treatment has been completed.\n\nMaintenance Phase:\n\nLenalidomide: 10 mg orally on days 1-21 or each 28 day cycle of maintenance. Maintenance begins after BiRD treatment has been completed.","id":"OG000","title":"Car-BiRD Therapy"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"28 participants achieved CR or sCR.","reportingStatus":"POSTED","timeFrame":"From start of study up to Revlimid Maintenance Cycle 4.","title":"MRD Negativity Following CarBiRD Regimen","type":"SECONDARY","unitOfMeasure":"Participants"}